Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Dec;27(19):2034-2041.
doi: 10.1177/2047487319825510. Epub 2019 Jan 30.

Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis

Safi U Khan  1 , Zain Ul Abideen Asad  2 , Muhammad U Khan  1 , Swapna Talluri  3 , Farman Ali  4 , Muhammad Shahzeb Khan  5 , Ahmad N Lone  1 , Farouk Mookadam  6 , Richard A Krasuski  7 , Edo Kaluski  8
Affiliations
Meta-Analysis

Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis

Safi U Khan et al. Eur J Prev Cardiol. 2020 Dec.

Abstract

Background: The safety and efficacy of aspirin for the primary prevention of cardiovascular disease in patients with diabetes mellitus remains controversial.

Design: A meta-analysis to investigate the effects of aspirin for the prevention of cardiovascular disease in diabetes mellitus.

Methods: Ten randomized controlled trials were selected using MEDLINE, EMBASE and CENTRAL databases until 27 September 2018. Risk ratios (RRs) with 95% confidence intervals (CIs) and risk differences (RDs) reported as incident events per 1000 person-years were calculated.

Results: In 33,679 patients, aspirin did not significantly reduce the risk of major adverse cardiovascular outcomes (RR 0.93, 95% CI 0.87-1.00, P = 0.06; RD -0.68 incident cases per 1000 person-years (95% CI -1.54, 0.17)), cardiovascular mortality (RR 0.95, 95% CI 0.83-1.09, P = 0.49; RD 0.11 incident cases per 1000 person-years (95% CI -0.80, 1.02)), myocardial infarction (RR 0.91, 95% CI 0.75-1.11, P = 0.36; RD -0.66 incident cases per 1000 person-years (95% CI -2.07, 0.75)), or stroke (RR 0.91, 95% C, 0.76-1.10, P = 0.33; RD -0.55 incident cases per 1000 person-years (95% CI -1.57, 0.47)). There was a significantly higher risk of total bleeding associated with aspirin (RR 1.29, 95% CI 1.07-1.55, P = 0.01; RD 1.49 incident cases per 1000 person-years (95% CI 0.36, 2.61)).

Conclusion: The use of aspirin for primary prevention of cardiovascular disease in patients with diabetes mellitus increases the risk of total bleeding without reducing the risk of major adverse cardiovascular outcomes.

Keywords: Cardiovascular disease; aspirin; diabetes mellitus; primary prevention.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow chart showing study selection process.
Figure 2.
Figure 2.
Forest plot comparing aspirin versus control for major adverse cardiovascular events (MACEs), cardiovascular mortality, myocardial infarction (MI) and stroke.
Figure 3.
Figure 3.
Forest plot comparing aspirin versus control for safety outcomes.
See this image and copyright information in PMC

Comment in

References

    1. Mattioli AY, Manenti A and Farinetti A. Sex differences in adherence to guidelines in aspirin prescription in a population of low-risk cardiovascular patients. Eur J Prey Cardiol 2018; 25: 606–607. - PubMed
    1. Eindhoven DC, Hilt AD, Zwaan TC, et al. Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment – the Netherlands claims database. Eur J Prev Cardiol 2018; 25: 181–189. - PubMed
    1. Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 2018; 379: 1529–1539. - PubMed
    1. Janssen VE, Visseren FL, de Boer A, et al. Combined use of polypill components in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2018; 25: 1523–1531. - PubMed
    1. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–2381. - PMC - PubMed

MeSH terms